Zoetis Stock (NYSE:ZTS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$175.18

52W Range

$144.80 - $201.92

50D Avg

$188.79

200D Avg

$179.32

Market Cap

$79.41B

Avg Vol (3M)

$1.85M

Beta

0.89

Div Yield

$1.73 (1.23%)

ZTS Company Profile


Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

14,100

IPO Date

Feb 01, 2013

Website

ZTS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Other Pharmaceuticals$1.28B--
Vaccines$1.77B--
Total Products and Services$8.47B--
Parasiticides$1.95B--
Other Non Pharmaceuticals$254.00M--
Medicated Feed Additives$354.00M--
Dermatology$1.43B--
Contract Manufacturing and Human Health Diagnostics$78.00M$86.00M$82.00M
Anti-infective Products$1.06B--
Animal Health Diagnostics$376.00M--

Fiscal year ends in Dec 23 | Currency in USD

ZTS Financial Summary


Dec 23Dec 22Dec 21
Revenue$8.54B$8.08B$7.78B
Operating Income$3.22B$2.89B$2.75B
Net Income$2.34B$2.11B$2.04B
EBITDA$3.22B$3.04B$2.92B
Basic EPS$5.08$4.51$4.29
Diluted EPS$5.07$4.49$4.27

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 04, 24 | 12:15 PM
Q2 24Aug 06, 24 | 11:50 AM
Q1 24May 02, 24 | 12:00 AM

Peer Comparison


TickerCompany
EBSEmergent BioSolutions Inc.
ELANElanco Animal Health Incorporated
ITCIIntra-Cellular Therapies, Inc.
HLNHaleon plc
VTRSViatris Inc.
ALVOAlvotech
NBIXNeurocrine Biosciences, Inc.
TAKTakeda Pharmaceutical Company Limited
ASRTAssertio Holdings, Inc.
BHCBausch Health Companies Inc.
TEVATeva Pharmaceutical Industries Limited
CTLTCatalent, Inc.
PETQPetIQ, Inc.
AMPHAmphastar Pharmaceuticals, Inc.